Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia.
Yoshida N.
Int J Hematol. 2024 Mar;119(3):240-247. doi: 10.1007/s12185-023-03564-4. Epub 2023 Mar 3.
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies.
Frigault MJ, Graham CE, Berger TR, Ritchey J, Horick NK, El-Jawahri A, Scarfò I, Schmidts A, Haradhvala NJ, Wehrli M, Lee WH, Parker AL, Wiggin HR, Bouffard A, Dey A, Leick MB, Katsis K, Elder EL, Dolaher MA, Cook DT, Chekmasova AA, Huang L, Nikiforow S, Daley H, Ritz J, Armant M, Preffer F, DiPersio JF, Nardi V, Chen YB, Gallagher KME, Maus MV.
Blood. 2024 Sep 12;144(11):1153-1167. doi: 10.1182/blood.2024024104.
Of gains and losses: SAMD9/SAMD9L and monosomy 7 in myelodysplastic syndrome.
Cammenga J.
Exp Hematol. 2024 Jun;134:104217. doi: 10.1016/j.exphem.2024.104217. Epub 2024 Apr 20.
Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.
Iguchi A, Cho Y, Sugiyama M, Terashita Y, Ariga T, Hosoya Y, Hirabayashi S, Manabe A, Hara K, Aiba T, Shiokawa T, Tada H, Sato N.
Int J Hematol. 2017 Aug;106(2):291-298. doi: 10.1007/s12185-017-2235-z. Epub 2017 Apr 11.
Marrow failure.
Bagby GC, Lipton JM, Sloand EM, Schiffer CA.
Hematology Am Soc Hematol Educ Program. 2004:318-36. doi: 10.1182/asheducation-2004.1.318.
Single Large-Scale Mitochondrial DNA Deletion Syndromes.
Goldstein A, Falk MJ.
2003 Dec 17 [updated 2023 Sep 28]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Deficiency of Adenosine Deaminase 2: Clinical Manifestations, Diagnosis, and Treatment.
Grim A, Veiga KR, Saad N.
Rheum Dis Clin North Am. 2023 Nov;49(4):773-787. doi: 10.1016/j.rdc.2023.06.004. Epub 2023 Aug 1.
Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function.
Aluri J, Bach A, Kaviany S, Chiquetto Paracatu L, Kitcharoensakkul M, Walkiewicz MA, Putnam CD, Shinawi M, Saucier N, Rizzi EM, Harmon MT, Keppel MP, Ritter M, Similuk M, Kulm E, Joyce M, de Jesus AA, Goldbach-Mansky R, Lee YS, Cella M, Kendall PL, Dinauer MC, Bednarski JJ, Bemrich-Stolz C, Canna SW, Abraham SM, Demczko MM, Powell J, Jones SM, Scurlock AM, De Ravin SS, Bleesing JJ, Connelly JA, Rao VK, Schuettpelz LG, Cooper MA.
Blood. 2021 May 6;137(18):2450-2462. doi: 10.1182/blood.2020009620.
Efficacy of tocilizumab therapy in a patient with severe pancytopenia associated with a STAT3 gain-of-function mutation.
Wang W, Liu L, Hui X, Wang Y, Ying W, Zhou Q, Hou J, Yang M, Sun B, Sun J, Wang X.
BMC Immunol. 2021 Mar 17;22(1):19. doi: 10.1186/s12865-021-00411-1.
Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial.
Shimamura A, Maschan A, Bennett C, Samarasinghe S, Farrar JE, Li CK, Sirachainan N, Pongtanakul B, Komvilaisak P, Zubarovskaya L, Rothman JA, Walkovich K, Nakano TA, Bertuch AA, Ferrao A, Bhat R, Hanna R, Overholt K, Boklan J, Wong TF, Wang Q, Urban P, Strahm B, Wang W, Vlachos A, Williams DA.
Blood Adv. 2025 Aug 12;9(15):3728-3738. doi: 10.1182/bloodadvances.2024015102.
